# Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

> **NCT00206518** · PHASE2 · COMPLETED · sponsor: **Mothaffar Rimawi** · enrollment: 167 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Taxotere/Docetaxel
- **DRUG:** Adriamycin/Cytoxan
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT00206518
- **Lead sponsor:** Mothaffar Rimawi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-10-10
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206518, "Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00206518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*